Northern Financial Advisors Inc Reduces Stock Position in Amgen Inc. $AMGN

Northern Financial Advisors Inc cut its stake in Amgen Inc. (NASDAQ:AMGN) by 42.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,961 shares of the medical research company’s stock after selling 1,457 shares during the period. Northern Financial Advisors Inc’s holdings in Amgen were worth $642,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. West Family Investments Inc. grew its position in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares during the last quarter. Viawealth LLC grew its position in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares during the last quarter. LOM Asset Management Ltd grew its position in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the last quarter. Smith Salley Wealth Management grew its position in shares of Amgen by 0.3% in the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after purchasing an additional 30 shares during the last quarter. Finally, Sittner & Nelson LLC grew its position in shares of Amgen by 0.4% in the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Morgan Stanley increased their price target on shares of Amgen from $309.00 to $326.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Finally, Mizuho increased their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Stock Down 1.4%

Shares of NASDAQ AMGN opened at $350.16 on Tuesday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm’s 50 day moving average price is $362.40 and its 200 day moving average price is $338.35. The firm has a market cap of $188.97 billion, a P/E ratio of 24.61, a price-to-earnings-growth ratio of 3.71 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the business earned $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.18 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.